Therapeutic Area
Committed to addressing unmet medical needs
-
Oncology
OncologyXZenith focuses on the layout of breast cancer, NSCLC and solid tumor. A comprehensive layout of the major breast cancer targets was developed.More -
Digestive
DigestiveXZenith focuses on peptic ulcer disease. The independently developed PPI has been approved for marketing.More -
NASH
NASHThe product is in the clinical stage.More
Technology Platform
Small Molecule
Innovative Pipeline
-
Small Molecule
-
Biological
-
License-in
Oncology
-
Therapeutic areaDrug NameIndicationTargetRightsPre-clinicalINDClinical phaseⅠⅡⅢNDA
-
Learn more
Breast cancer and other solid tumors
XZP-3287 BirociclibHR+/HER2- End line, mono, late stage
HR+/HER2- (Combo w/ Fulvestrant, 2L)
HR+/HER2- (Combo w/ AI 1L)
CDK4/6 (BBB penetrated)GlobalLL single drug registration clinicalXZP-KM118HER2+
HER2SL PharmPertuzumab BiosimilarsXZP-KM257Breast cancer, Cholangiocarcinoma, Gastric cancer, Bladder cancer etc
HER2/HER2 （Bispecific）GlobalBIC
XZP-KM501Breast cancer, Colorectal cancer，Gastric cancer or medium level of HER2+ solid tumors
HER2/HER2 （Bispecific-ADC）GlobalBIC
XZB-0002HR+ and or ER+ Breast cancer
SERDChinaANDA -
Learn more
NSCLC
XZP-36212nd generation ALKi-resistant NSCLC
ALKi (1L)
ALK；ROS1 （New generation TKI)GlobalXZP-5955NSCLC with ROS1 fusion and mutations
NTRK、ROS1Global -
Learn more
Solid tumor
XZP-5955Locally advanced/Metastatic solid tumors with NTRK fusion and mutations
NTRK、ROS1GlobalXZB-0004NSCLC（Combo w/ PD1）
AML
AXLGreater ChinaFICFICXZB-6877TNBC, Ovarian cancer, SCLC, etc.
UndisclosedGlobalXZP-KM602Multiple solid tumors
UndisclosedP270/280/283/291
119/216/2184 small molecule drugs + 3 large molecule drugs, 8 under research, solid tumor
UndisclosedGlobalKM-259Solid tumor
UndisclosedGlobalXZB-00033 under development, Solid tumor
Protein degraderGreater ChinaFIC
Digestive disease
-
Therapeutic areaDrug NameIndicationTargetRightsPre-clinicalINDClinical phaseⅠⅡⅢNDA
-
Learn more
Digestive disease
KBP-3571 (Anaprazole Sodium)DU (Duodenal Ulcer)
PPIsGlobal
NASH
-
Therapeutic areaDrug NameIndicationTargetRightsPre-clinicalINDClinical phaseⅠⅡⅢNDA
-
Learn more
NASH
XZP-5610NASH
FXRGlobal
XZP-6019NASH
UndisclosedGlobalFIC IND获批
Other
-
Therapeutic areaDrug NameIndicationTargetRightsPre-clinicalINDClinical phaseⅠⅡⅢNDA
-
Learn more
Andrologic
XZP-5849ED
PAH
PDE-5GlobalFast Track
Global business
Partnering
XZenith attaches great importance to the cooperation and communication with domestic and foreign universities and Biotech companies. Actively seek for the cooperative development projects of international frontier technology platforms. If you have any business cooperation intention, please contact our BD department: bd@xuanzhubio.com
9th Floor, North Tower of CP Center, No.20 Jin He East Avenue,Chaoyang District,Beijing,China
Tel：010-5765 4567
Email：XZGROUP@xuanzhubio.com
Copyright © 轩竹生物科技有限公司保留所有权利 冀ICP备2020028968号-2
